Background: Radiotherapy can be an effective treatment for prostate cancer, but radiorecurrent tumours do develop. Considering prostate cancer heterogeneity, we hypothesised that primitive stem-like cells may constitute the radiation-resistant fraction.
Precision radiotherapy (external beam or brachytherapy) is an important treatment for localised prostate cancer. However, despite improvements in targeting and dose, one-third of patients still fail because of local or systemic resistance (Brawer, 2002; Catton et al, 2003; Ishkanian et al, 2010) . Metastases following radiotherapy are a significant clinical problem that requires an improved understanding of the biology of treatment-resistant phenotypes Jones, 2011) . The use of in vitro cell line models of prostate cancer has demonstrated that clones of radioresistant cells emerge post irradiation (Bromfield et al, 2003; van Oorschot et al, 2013) . There have also been radiation response studies using normal prostate tissue and primary cells from normal biopsies (Kiviharju-af Hallstrom et al, 2007; Jaamaa et al, 2010; Zhang et al, 2011) . However, none of these studies addressed the phenotype of the resistant clones. We, and others, have shown that a cellular hierarchy exists in several cancer types and in both prostate cancer epithelium and normal prostate epithelium (Collins et al, 2001; Hudson et al, 2001; Miller et al, 2005; Visvader and Lindeman, 2008; Maitland et al, 2010; Clevers, 2011) . These studies demonstrated that the more stem-like cells (SCs), at the beginning of the hierarchy, have more clonogenic and tumourigenic potential than the more differentiated cells. Moreover, in glioblastoma, it was demonstrated that the primitive cells were more resistant to radiotherapy than the majority of cells within the tumour (Bao et al, 2006) . This finding has been backed up by other studies suggesting that the SCs may be directly responsible for tumour recurrence (Chiou et al, 2008; Diehn et al, 2009b; Conley et al, 2012; Chen et al, 2013) . In light of these findings, we hypothesised that the SCs in prostate cancer would be more resistant to irradiation than the more differentiated populations. Using the same markers we had previously used to isolate the normal and malignant prostate hierarchy (Collins et al, 2001; Richardson et al, 2004; Collins et al, 2005) , we show here that the most undifferentiated cells in both benign and malignant primary cultures are more resistant to irradiation. This resistance is conferred by heterochromatin, which protects the cells from the DNA-damaging effects of radiation.
MATERIALS AND METHODS
Tissue collection, isolation and culture of tumour cells. Human prostate tissue was obtained with patient's consent and full ethical approval from patients undergoing radical prostatectomy and channel transurethral resection (TURP) for prostate cancer and from patients undergoing transurethral resection for benign prostatic hyperplasia (BPH) ( Table 1) . Grade and stage of tumour were confirmed by histologic examination of representative fragments by a uropathologist. Epithelial cultures were prepared and characterised as described previously (Collins et al, 2001) . Cell cultures were maintained in stem cell media (SCM) consisting of -B2  5  T  58  Benign  -B3  5  T  77  Benign  -B4  4  T  88  Benign  -B5  2 þ 6  C  72  Benign  -B6  5  T  83  Benign  -B7  3  T  82  Benign  -B8  4  T  65  Benign  -B9  3  T  83  Benign  -B10  6  T  77  Benign  -B11  5  T  67  Benign  -B12  6  T  74  Benign  -B13  1  T  -Benign  -B14  2  T  72  Benign  -B15  3  T  71  Benign  -B16  3  T  62  Benign  -B17  3  T  84  Benign  -B18  4  R  61 Benign -
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Abbreviations: C ¼ cystectomy; R ¼ radical prostatectomy; T ¼ transurethral resection of the prostate.
keratinocyte growth medium supplemented with EGF, bovine pituitary extract (Life Technologies Ltd, Paisley, UK), 2 ng ml (committed basal (CB) ) cells were isolated by magnetic-activated cell sorting (MACS; Miltenyi Biotec, Surrey, UK) as described previously (Richardson et al, 2004; Collins et al, 2005) . SC cells are the most primitive cells, with TA cells being a progenitor population and CB cells being further along the differentiation hierarchy.
Irradiation of cells. To irradiate cells, an RS2000 X-Ray Biological Irradiator was used that contains a Comet MXR-165 X-Ray Source (Rad-Source Technologies Inc., Suwanee, GA, USA). A dose of 2 or 10 Gy was administered with a dose rate of 0.02 or 0.08 Gy s À 1 . To determine colony-forming ability post irradiation, primary cultures were irradiated as a whole population and subsequently sorted. To assay DNA damage, in response to radiation, primary cells were sorted into their respective populations before irradiation because of the rapid nature of DNA damage formation.
Clonogenic recovery. Primary prostate cultures were irradiated (2 Gy) and immediately sorted into subpopulations (SC, TA and CB), counted and plated on to 35-mm collagen-coated plates (BD Biocoat, BD Biosciences, Oxford, UK) at a density of 100 cells per well in the presence of irradiated STO feeder cells. For treatment with HDAC inhibitor, cells were treated with 0.6 mM of Trichostatin A (TSA; Sigma-Aldrich Company Ltd, T1952) for 1 h and 30 min and then irradiated (2 Gy) and treated as above. Colonies were subsequently scored if they contained 432 cells (at least 5 population doublings, which are considered as self-sustaining colonies with proliferation potential (Puck and Marcus, 1956; Francipane et al, 2008) , usually B14 days after treatment. Colonies were visualised by staining with 1% crystal violet/10% ethanol/PBS.
Alkaline and neutral comet assays. Comet assays were modified from Sturmey et al (2009) . Primary prostate epithelial cells were separated into SC, TA and CB cells, resuspended in 25 ml PBS and irradiated. At 30 min post irradiation, 225 ml of low-melting-point (LMP) agarose was added to the cells, mixed and pipetted onto an agarose-coated slide (1% agarose in PBS). A clean coverslip was placed on top and slides placed at 4 1C for 15 min. Once set, coverslips were removed and slides placed in lysis buffer (2.5 M NaCl, 1 mM EDTA, 10 mM Tris, 10% DMSO, 1% Triton X-100, pH 10) overnight at 4 1C. For the alkaline comet assays, slides were incubated in alkaline solution (0.3 M NaOH, 1 mM EDTA, pH 13) for 40 min at 4 1C, and then electrophoresed at 23 V, 300 mA in the same alkaline solution (for 40 min on ice). Subsequently, they were incubated for 2 Â 10 min in neutralising buffer (0.4 M Tris, pH 7.5). For the neutral comet assays, slides were incubated in TBE electrophoresis buffer at 4 1C for 40 min and electrophoresed at 25 V for 20 min. For both assays SYBRgold was applied (1 : 10 000 in TE buffer, 10 mM Tris-Cl, pH 7.5, 1 mM EDTA) to stain the DNA. Comets were measured using CometScore freeware (TriTek Corp., Sumerduck, VA, USA) following image capture using a Nikon Eclipse TE300 fluorescent microscope (Nikon, Surrey, UK) with a Â 10 lens.
Immunofluorescence. Immunocytochemistry was conducted on sorted
À (TA) and a 2 b 1 integrin lo (CB) primary cells. The cell isolates were allowed to adhere for 2 h onto collagen-coated slides, and in some experiments were treated with 0.6 mM of TSA (Sigma-Aldrich Company Ltd T1952) for 1 h and 30 min and irradiated (2 Gy) before fixing in 2% paraformaldehyde/PBS/0.2% Triton X-100, pH 8.2 (20 min), then permeabilised with 0.5% NP40/PBS (20 min). Cells were then blocked (2% BSA/1% normal goat serum/PBS) and incubated in primary antibody in 3% BSA/PBS at 4 1C overnight followed by washes in 0.5% BSA/0.175% Tween-20/PBS. Secondary antibody was added for 45 min in 3% BSA/PBS followed by washes. Slides were mounted with Vectashield with DAPI (Vector Laboratories, Peterborough, UK). Primary antibodies used were as follows: anti-phospho-Histone H2A.X (Ser139), clone JBW301 (Millipore, Watford, UK); 53BP1 (Alexis Biochemicals, Exeter, UK, ALK-210-419 or Abcam, Cambridge, UK, ab36823); phospho-Chk2 (Thr68; Cell Signaling Technology, Hitchin, UK, 2661); phospho-(Ser/Thr) ATM/ATR substrate antibody (Cell Signaling Technology 2851); H3K9me3 (histone H3(trimethylated at lysine 9); Diagenode, Denville, NJ, USA, pAb-056-050); Ki67 (Abcam ab15580); H3K27me3 (histone H3(trimethylated at lysine 27); Millipore 17-622). Secondary antibodies were goat anti-mouse AlexaFluor-488 (Life Technologies Ltd A11029) and goat anti-rabbit AlexaFluor-568 (Life Technologies Ltd A11036).
Confocal images were acquired on Zeiss LSM 510 and Zeiss LSM Meta Laser confocal microscopes (Zeiss, Cambridge, UK). Colocalisation analysis, Pearson's correlation, line scan analysis and fluorescence intensity measurements were carried out using Volocity software (Improvision, Perkin Elmer, Waltham, MA, USA). For foci counting, images were captured using a Nikon Eclipse TE300 fluorescent microscope (Nikon, Surrey, UK) with a Â 63 oil immersion lens and foci were counted using the multi-point tool in ImageJ software (Town of Mount Royal, QC, Canada). Statistical analysis. Median values of each analysis were calculated. Significance was assessed using the Wilcoxon rank-sum test or t-test for smaller sample numbers where stated (GraphPad Prism, La Jolla, CA, USA). The P-values indicating statistical significance are displayed.
RESULTS
SCs are more radioresistant than progenitor cells. To establish whether prostate SCs are more resistant to irradiation than progenitors, we determined the potential of each population to initiate colonies (at clonal density) following irradiation. Our rationale for using 2 Gy was to mimic the clinical daily dose of 2 Gy that has been routinely administered to patients (Bromfield et al, 2003) . Primary cells, derived from patients with BPH, and prostate cancer, including those who had undergone androgen-ablation therapy, were irradiated, sorted into SCs and progenitors (TA and CB) and plated to determine colony-forming efficiency (CFE) that is represented as surviving fraction (SF) after 2 Gy (SF2Gy; Figure 1A and B). The highest SF2Gy (post irradiation) was observed in the SCs, independent of disease status ( Figure 1A and B) . To investigate the consequences of irradiation on each cell type, DNA damage was measured following radiation in each population ( Figure 1C and D) . To do this we used comet assays to measure DNA damage directly, following radiation doses of 2 and 10 Gy. Alkaline comet assays were used to measure single-strand breaks (SSBs), double-strand breaks (DSBs), alkali labile sites, DNA crosslinks and incomplete excision repair (Singh et al, 1988; Tice et al, 2000; Nandhakumar et al, 2011; Swain and Subba Rao, 2011) . We observed comparable damage in each population, with a clear dose-dependent increase (up to 10 Gy; Figure 1C ). In contrast, using the neutral comet assay, we observed that the SCs incurred significantly less damage than either the TA or CB populations ( Figure 1D ). Moreover, there was no significant difference in DNA damage with increasing dose. The neutral comet assay has a bias for measuring lethal DSBs (Ostling and Johanson, 1984; Singh et al, 1988; Lemay and Wood, 1999; Wojewodzka et al, 2002; Van Kooij et al, 2004; Swain and Subba Rao, 2011) . This suggests that the SCs are protected from this specific type of damage compared with the progenitor (TA) and more differentiated (CB) cells. As observed with the colony-forming assay, this effect on DNA damage was independent of disease status.
SCs sustain less DSBs than progenitors. To confirm this finding, we investigated the DSB DNA damage response further. Primary cells were sorted, irradiated and fixed at 30 min post irradiation. Cells were then stained for gH2AX and 53BP1 DNA damage nuclear foci, indicative of DSBs (Paull et al, 2000; Belyaev, 2010; Mah et al, 2010) ( Figure 2A ). Approximately 90% of TA and CB cell nuclei showed evidence of DSBs, whereas significantly fewer (30-50%) SCs sustained DSBs ( Figure 2B -E). These results are in agreement with our findings using the neutral comet assay, showing evidence of DSBs in the majority of TA and CB cells, but only in a minority of SCs. We also investigated the downstream events following induction of DNA damage by staining the cell populations for members of the ATM-Chk2 DSB DNA damage pathway (Figure 3) . Again, we observed that the percentage of SCs containing ATM/ATR phosphorylated substrates and phospho-Chk2
Thr68 was significantly less than either of the progenitor populations, again reinforcing our findings that SCs sustain less DSBs.
Although the majority of SCs appear to sustain no damage, we wanted to know if the minority subpopulation that did sustain damage could undertake DNA repair. To do this, the number of foci per cell nucleus was quantified. It was clear that in all cell types (SC, TA, CB), and in all patients, DNA repair was taking place, as evidenced by a significant reduction in the number of foci per cell nucleus at 24 h compared with 30 min (Figure 4 ).
SCs are less proliferative and have increased heterochromatin.
As SCs appeared to sustain less DNA damage following irradiation, we hypothesised that they may have an inherent protection mechanism. We had previously demonstrated that the SCs are less proliferative (Lang et al, 2010) , and hence we quantified the number of cells expressing the proliferation marker Ki67 ( Figure 5A ). Primary cells from six patients were sorted as previously described and stained with an antibody against Ki67. We found that the percentage of SCs expressing Ki67 was significantly less than either the TA or CB cells, suggesting that the progenitor (TA) and more differentiated (CB) cells are more proliferative than the SCs ( Figure 5A ). Statistical significance values were measured using the Wilcoxon rank-sum test (*Po0.05, **Po0.01).
A B
One other mechanism by which a cell could sustain less damage is by packing more DNA into heterochromatin. Storch et al (2010) found that growing cells in a 3D formation led to increased chromatin condensation, which subsequently resulted in radioresistance. Furthermore, when measuring the number of DSBs in euchromatin vs heterochromatin in monolayer cells, the authors found a ratio of 2 : 1, that is, fewer breaks in heterochromatin. When we examined heterochromatin marks (H3K27me3 and H3K9me3) in each cell population, we observed that a proportion of SCs appeared to have increased heterochromatin content compared with the other cell types (TA and CB) ( Figure 5B ). We quantified heterochromatin by measuring the fluorescence intensity of sorted cells ( Figure 5C ) as well as flow cytometry where cells were co-stained with CD49b (a 2 b 1 integrin) and CD133 to distinguish the three populations ( Figure 5D ). This showed that SCs had significantly increased heterochromatin compared with the progenitor (TA) and more differentiated (CB ) cells.
To confirm that heterochromatin conferred a protective effect to the cells, we carried out dual staining of DNA damage foci and heterochromatin that showed preferential formation of foci located almost exclusively at nuclear sites devoid of heterochromatin staining (Figure 5Ei ). In addition, several SCs were observed to have high levels of heterochromatin throughout the nucleus that corresponded with an absence of foci (Figure 5Eii ). hypothesised that manipulating chromatin status in the SCs would render them more sensitive to radiation treatment. To achieve this, cells were sorted and treated with a low dose of HDAC inhibitor (0.6 mM TSA) for 1 h and 30 min followed by 2 Gy irradiation. The treated cells were then fixed 30 min post irradiation and subsequently stained for DNA damage foci ( Figure 6A ). The effect of TSA was confirmed by western blot using lysates from unsorted cells for acetylated histones where we observed an increase in histone acetylation following treatment ( Figure 6B ). This is known to correlate with chromatin decondensation (Toth et al, 2004) . Following the combination treatment, the number of SCs sustaining DSBs, as evidenced by increased number of cells containing foci, significantly increased (Figure 6Ai ). There was no significant increase in the percentage of TA or CB cells containing foci as the majority of these cells contain foci following radiation alone, and hence the effect is already saturated. On quantifying foci number in the SCs we found no increase in number of foci per cell nucleus following TSA treatment (Figure 6Aii ). We then assessed the effect of combination treatment on clonogenic recovery and found that the SCs formed significantly fewer colonies following combination treatment compared with irradiation alone ( Figure 6C ). We concluded from this experiment that the HDAC inhibitor had sensitised the SCs to radiation treatment.
DISCUSSION
In this study, we present evidence demonstrating that primitive prostate SCs, from freshly cultured patient tissues, are more radioresistant than more differentiated cells, which we show to be independent of patient disease status. We propose that the SCs, by having higher levels of heterochromatin, sustain fewer lethal DSBs, which contributes to increased survival. Significantly, by treating this population with an HDAC inhibitor, DNA damage was increased, resulting in sensitisation of the cells to radiation, thus reducing survival. Using colony-forming assays, we were able to demonstrate that SCs were less affected by irradiation as compared with the progenitor cells. Although the overall induction of DNA damage was similar between populations (alkaline comet assays), we observed a significant reduction in the percentage of SCs sustaining lethal DSBs (neutral comet assays and DNA damage foci). Lack of activation of the ATM/ATR DNA damage signaling pathways correlated with this population. By quantifying the number of foci in the minority of SCs positive for foci, as well as TA and CB cells, we confirmed that DNA repair was undertaken in all cell types.
We present evidence here that SCs sustain less DNA damage because of increased heterochromatin content. Our results pointed towards the use of HDAC inhibitors, in combination with radiation, as a therapy for prostate cancer. HDAC inhibitors have been heavily investigated for their clinical use and are also in clinical trials for prostate cancer (Marchion and Munster, 2007; Frew et al, 2009; Atadja, 2011) . There are encouraging results with HDAC inhibitors targeting proliferating and nonproliferating cells (Burgess et al, 2004) . However, they are often being employed as toxins, rather than response modifiers, the latter being what we propose based on the data in Figure 6 . Our work shows that a short exposure to sublethal doses of HDAC inhibitors may be enough to sensitise prostate SCs. It is also possible that less damage is sustained because of the less proliferative nature of SCs. It has previously been shown that adult SCs are predominantly quiescent and that this can reduce accumulation of mutations through DNA replication and contribute to therapy resistance (Mohrin et al, 2010; Blanpain et al, 2011; Li and Bhatia, 2011) . Using the vital dye PKH26, we were able to show that prostate stem cells undergo up to four population doublings (in monolayer culture) before exiting the cell cycle (Lang et al, 2010) . We also observed here that significantly more progenitor and more differentiated cells (TA and CB cells) are in cycle compared with the SCs.
In summary, radiorecurrent prostate cancer is a significant problem for both physicians and patients because of local and systemic resistance (Ishkanian et al, 2010) . The heterogeneity of prostate cancers has been well documented, yet we are the first to report the radiation-resistant phenotype of the primitive SCs and the mechanism behind this resistance. Other radiation resistance mechanisms have been documented, such as increased scavenging of reactive oxygen species (ROS) in breast cancer stem cells and increased efficiency of DNA repair and DNA damage response in glioblastoma cancer stem cells (Bao et al, 2006; Woodward and Bristow, 2009; Diehn et al, 2009a) . It remains to be seen whether those play an additional role in radiation resistance of prostate tumours.
